Joel LeMaoult

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4556615/publications.pdf

Version: 2024-02-01

73 papers 5,900 citations

38 h-index 71 g-index

75 all docs

75 docs citations

75 times ranked 5271 citing authors

#	Article	IF	CITATIONS
1	HLA-G: from biology to clinical benefits. Trends in Immunology, 2008, 29, 125-132.	6.8	336
2	HLA-G. Advances in Immunology, 2015, 127, 33-144.	2.2	334
3	Direct Link Between mhc Polymorphism, T Cell Avidity, and Diversity in Immune Defense. Science, 2002, 298, 1797-1800.	12.6	304
4	HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7064-7069.	7.1	302
5	Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood, 2008, 111, 4862-4870.	1.4	297
6	HLAâ€G upâ€regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB Journal, 2005, 19, 1-23.	0.5	266
7	Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood, 2007, 109, 2040-2048.	1.4	236
8	Age-related CD8 T Cell Clonal Expansions Constrict CD8 T Cell Repertoire and Have the Potential to Impair Immune Defense. Journal of Experimental Medicine, 2004, 200, 1347-1358.	8.5	229
9	Trogocytosis-based generation of suppressive NK cells. EMBO Journal, 2007, 26, 1423-1433.	7.8	210
10	A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. European Urology, 2015, 68, 267-279.	1.9	204
11	Heteroclitic Immunization Induces Tumor Immunity. Journal of Experimental Medicine, 1998, 188, 1553-1561.	8.5	191
12	Effect of age on humoral immunity, selection of the B-cell repertoire and B-cell development. Immunological Reviews, 1997, 160, 115-126.	6.0	173
13	CD8+CD28- T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunological Reviews, 2001, 182, 201-206.	6.0	173
14	The immunosuppressive molecule HLA-G and its clinical implications. Critical Reviews in Clinical Laboratory Sciences, 2012, 49, 63-84.	6.1	157
15	CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood, 2007, 110, 3936-3948.	1.4	129
16	ILT2/HLAâ€G interaction impairs NKâ€cell functions through the inhibition of the late but not the early events of the NKâ€cell activating synapse. FASEB Journal, 2010, 24, 689-699.	0.5	101
17	The Dual Role of HLA-G in Cancer. Journal of Immunology Research, 2014, 2014, 1-10.	2.2	95
18	Age-Related Dysregulation in CD8 T Cell Homeostasis: Kinetics of a Diversity Loss. Journal of Immunology, 2000, 165, 2367-2373.	0.8	94

#	Article	IF	CITATIONS
19	Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Seminars in Cancer Biology, 2007, 17, 413-421.	9.6	94
20	The tolerogenic interplay(s) among HLA-G, myeloid APCs, and regulatory cells. Blood, 2011, 118, 6499-6505.	1.4	88
21	Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Molecular Immunology, 2006, 43, 2151-2160.	2.2	86
22	HLA-G–dependent suppressor cells: Diverse by nature, function, and significance. Human Immunology, 2008, 69, 700-707.	2.4	86
23	Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors. Cellular and Molecular Life Sciences, 2012, 69, 4041-4049.	5.4	83
24	Recent advances on the non-classical major histocompatibility complex class I HLA-G molecule. Tissue Antigens, 2010, 75, 201-206.	1.0	81
25	HLA-G Expression in Human Embryonic Stem Cells and Preimplantation Embryos. Journal of Immunology, 2011, 186, 2663-2671.	0.8	73
26	HLA-G expression levels influence the tolerogenic activity of human DC-10. Haematologica, 2015, 100, 548-557.	3.5	69
27	HLA-G in Transplantation: A Relevant Molecule for Inhibition of Graft Rejection?. American Journal of Transplantation, 2003, 3, 11-16.	4.7	67
28	Novel landscape of HLA \hat{a} isoforms expressed in clear cell renal cell carcinoma patients. Molecular Oncology, 2017, 11, 1561-1578.	4.6	67
29	Inhibition of human $\hat{V^{3}9}\hat{V^{2}}$ T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Cellular and Molecular Life Sciences, 2011, 68, 3385-3399.	5.4	63
30	Maternal antigen presenting cells are a source of plasmatic HLA-G during pregnancy: Longitudinal study during pregnancy. Human Immunology, 2007, 68, 661-667.	2.4	62
31	CD8+PD-1–ILT2+ T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-G. Cancer Immunology Research, 2019, 7, 1619-1632.	3.4	62
32	The role of HLA-G in immunity and hematopoiesis. Cellular and Molecular Life Sciences, 2011, 68, 353-368.	5.4	60
33	Research on HLA-G: an update. Tissue Antigens, 2007, 69, 207-211.	1.0	57
34	In vivo identification of an <scp>HLA</scp> â€ <scp>G</scp> complex as ubiquitinated protein circulating in exosomes. European Journal of Immunology, 2013, 43, 1933-1939.	2.9	51
35	Immuno-tolerogenic functions of HLA-G: Relevance in transplantation and oncology. Autoimmunity Reviews, 2005, 4, 503-509.	5.8	50
36	Distinct mRNA microarray profiles of tolerogenic dendritic cells. Human Immunology, 2001, 62, 1065-1072.	2.4	45

#	Article	IF	Citations
37	Intercellular exchanges of membrane patches (trogocytosis) highlight the next level of immune plasticity. Transplant Immunology, 2006, 17, 20-22.	1.2	44
38	Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4. Oncolmmunology, 2017, 6, e1342023.	4.6	42
39	Exchanges of Membrane Patches (Trogocytosis) Split Theoretical and Actual Functions of Immune Cells. Human Immunology, 2007, 68, 240-243.	2.4	38
40	Different functional outcomes of intercellular membrane transfers to monocytes and T cells. Cellular and Molecular Life Sciences, 2010, 67, 1133-1145.	5.4	36
41	Synthetic HLAâ€G proteins for therapeutic use in transplantation. FASEB Journal, 2013, 27, 3643-3651.	0.5	34
42	Increased VH 11 and VH Q52 gene use by splenic B cells in old mice associated with oligoclonal expansions of CD5+ B cells. Mechanisms of Ageing and Development, 1998, 103, 111-121.	4.6	32
43	Nitric oxide produces HLAâ€G nitration and induces metalloproteaseâ€dependent shedding creating a tolerogenic milieu. Immunology, 2009, 126, 436-445.	4.4	32
44	Linking Two Immuno-Suppressive Molecules: Indoleamine 2,3 Dioxygenase Can Modify HLA-G Cell-Surface Expression 1. Biology of Reproduction, 2005, 73, 571-578.	2.7	30
45	First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G., 2021, 9, e001998.		30
46	Proper Regrafting of Ig-Like Transcript 2 after Trogocytosis Allows a Functional Cell–Cell Transfer of Sensitivity. Journal of Immunology, 2011, 186, 2210-2218.	0.8	29
47	Human melanoma cell secreting human leukocyte antigen–G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell. Human Immunology, 2009, 70, 1000-1005.	2.4	26
48	Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary. Frontiers in Immunology, 2020, 11, 2046.	4.8	25
49	Trogocytic intercellular membrane exchanges among hematological tumors. Journal of Hematology and Oncology, 2015, 8, 24.	17.0	22
50	Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets. Cancer Immunology, Immunotherapy, 2020, 69, 1237-1252.	4.2	22
51	Membrane redistributions through multi-intercellular exchanges and serial trogocytosis. Cell Research, 2010, 20, 1239-1251.	12.0	20
52	Identification of Circulating Nonclassic Human Leukocyte Antigen G (HLA-G)–Like Molecules in Exudates. Clinical Chemistry, 2011, 57, 1013-1022.	3.2	20
53	Pseudomonas aeruginosa Quorum Sensing Molecule N -(3-Oxododecanoyl)- l -Homoserine-Lactone Induces HLA-G Expression in Human Immune Cells. Infection and Immunity, 2015, 83, 3918-3925.	2.2	20
54	Tolerogenic Function of Dimeric Forms of HLA-G Recombinant Proteins: A Comparative Study In Vivo. PLoS ONE, 2011, 6, e21011.	2.5	19

#	Article	IF	CITATIONS
55	Expression and differential regulation of HLA-G isoforms in the retinal pigment epithelial cell line, ARPE-19. Human Immunology, 2017, 78, 414-420.	2.4	17
56	HLAâ€G inhibition of NKâ€eell cytolytic function is uncoupled from tumor cell lipid raft reorganization. European Journal of Immunology, 2012, 42, 700-709.	2.9	16
57	Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8+ T cells. Oncotarget, 2018, 9, 33160-33169.	1.8	16
58	Skin Immunity and Tolerance: Focus on Epidermal Keratinocytes Expressing HLA-G. Frontiers in Immunology, 2021, 12, 772516.	4.8	16
59	Role of the HLA-G immune checkpoint molecule in pregnancy. Human Immunology, 2021, 82, 353-361.	2.4	15
60	HLA-G5 expression by trophoblast cells: the facts. Molecular Human Reproduction, 2005, 11, 719-722.	2.8	13
61	The HLA-G Genetic Contribution to Bipolar Disorder: A Trans-Ethnic Replication. Immunological Investigations, 2018, 47, 593-604.	2.0	13
62	Human Hepatocytes and Differentiated Adult-Derived Human Liver Stem/Progenitor Cells Display <i>In Vitro</i> Immunosuppressive Properties Mediated, at Least in Part, through the Nonclassical HLA Class I Molecule HLA-G. Journal of Immunology Research, 2019, 2019, 1-13.	2.2	11
63	Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC. Frontiers in Immunology, 2020, 11, 608614.	4.8	11
64	Tumor infiltrating and peripheral CD4+ILT2+ T cells are a cytotoxic subset selectively inhibited by HLA-G in clear cell renal cell carcinoma patients. Cancer Letters, 2021, 519, 105-116.	7.2	11
65	Functional Evidence That Conserved TCR CDRα3 Loop Docking Governs the Cross-Recognition of Closely Related Peptide:Class I Complexes. Journal of Immunology, 2001, 167, 836-843.	0.8	10
66	Human Keratinocytes Inhibit CD4+ T-Cell Proliferation through TGFB1 Secretion and Surface Expression of HLA-G1 and PD-L1 Immune Checkpoints. Cells, 2021, 10, 1438.	4.1	9
67	HLA-G: a look back, a look forward. Cellular and Molecular Life Sciences, 2011, 68, 337-340.	5.4	8
68	Chronic lung allograft dysfunction is associated with an early increase of circulating cytotoxic CD4+CD57+ILT2+ T cells, selectively inhibited by the immune check-point HLA-G. Journal of Heart and Lung Transplantation, 2022, 41, 626-640.	0.6	8
69	Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation. PLoS ONE, 2016, 11, e0158907.	2.5	4
70	Multiplex bead-based immunoassay for the free soluble forms of the HLA-G receptors, ILT2 and ILT4. Human Immunology, 2016, 77, 720-726.	2.4	2
71	Immunosuppressive Properties of Epidermal Keratinocytes Differ According to Their Immaturity Status. Frontiers in Immunology, 2022, 13, 786859.	4.8	2
72	Extended <i>HLAâ€G</i> haplotypes in patients with ageâ€related macular degeneration. Hla, 2018, 92, 83-89.	0.6	1

ARTICLE IF CITATIONS

73 Trogocytosis and NK Cells in Mouse and Man., 2010,, 109-123.